BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11245656)

  • 1. Recombinant hirudin in clinical practice: focus on lepirudin.
    Greinacher A; Lubenow N
    Circulation; 2001 Mar; 103(10):1479-84. PubMed ID: 11245656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
    Yusuf S
    Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
    Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lepirudin for heparin-induced thrombocytopenia.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):94-5. PubMed ID: 9774965
    [No Abstract]   [Full Text] [Related]  

  • 6. Lepirudin anticoagulation for heparin-induced thrombocytopenia.
    Deitcher SR; Topoulos AP; Bartholomew JR; Kichuk-Chrisant MR
    J Pediatr; 2002 Feb; 140(2):264-6. PubMed ID: 11865285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lepirudin in the management of heparin-induced thrombocytopenia.
    Gajra A; Husain J; Smith A
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1131-41. PubMed ID: 18680447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
    Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
    Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Image of the month. Heparin-induced thrombocytopenia: stop all heparin therapy and treat with lepirudin.
    Bush RL; Lin PH; Lumsden AB
    Arch Surg; 2002 Feb; 137(2):221-2. PubMed ID: 11822964
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis.
    Dager WE; White RH
    Ann Pharmacother; 2001; 35(7-8):885-90. PubMed ID: 11485140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
    Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.
    Greinacher A; Janssens U; Berg G; Böck M; Kwasny H; Kemkes-Matthes B; Eichler P; Völpel H; Pötzsch B; Luz M
    Circulation; 1999 Aug; 100(6):587-93. PubMed ID: 10441094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass.
    Fabrizio MC
    J Extra Corpor Technol; 2001 May; 33(2):117-25. PubMed ID: 11467439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
    Greinacher A; Völpel H; Janssens U; Hach-Wunderle V; Kemkes-Matthes B; Eichler P; Mueller-Velten HG; Pötzsch B
    Circulation; 1999 Jan 5-12; 99(1):73-80. PubMed ID: 9884382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.
    Greinacher A
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):339-57. PubMed ID: 15151481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with lepirudin in heparin-induced thrombocytopenia. A case report].
    Nippert M; de Maistre E; Rodermann M; Vançon AC; Amrein D; Brembilla-Perrot B; Lecompte T; Zannad F; Aliot E
    Arch Mal Coeur Vaiss; 2002 Dec; 95(12):1234-8. PubMed ID: 12611047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for heparin-induced thrombocytopenia.
    Greinacher A
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S12-8. PubMed ID: 14593978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy for patients with heparin-induced thrombocytopenia marketed.
    Am J Health Syst Pharm; 1998 Jul; 55(14):1444. PubMed ID: 9676284
    [No Abstract]   [Full Text] [Related]  

  • 20. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.